Hypoparathyroidism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Hypoparathyroidism is an endocrine
disorder in which the parathyroid glands are either removed or produce
insufficient parathyroid hormone (PTH). The resulting decrease in PTH, which
controls calcium, phosphate, and vitamin D levels in the blood and bone, causes
derangements in mineral homeostasis, including hypocalcemia and
hyperphosphatemia. Hypoparathyroidism is most often acquired, caused by head
and neck surgery during which the parathyroid glands are either intentionally
or inadvertently removed or damaged; it can also be congenital, idiopathic, or
the result of an autoimmune disorder. Patients with Hypoparathyroidism most
often present with paresthesia, cramps, or tetany, but the disorder also may
manifest acutely with seizures, bronchospasm, laryngospasm, or cardiac rhythm
disturbances. In the postoperative setting, the presentation can be acute, with
tetany, cramping, tachycardia, and altered mental status dominating the
picture. The disorder occurs in both acquired and inherited forms.
- The prevalence of Hypoparathyroidism varies between 37 to 58
cases per 100,000 population in the USA
Thelansis’s “Hypoparathyroidism Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hypoparathyroidism
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Hypoparathyroidism across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Hypoparathyroidism Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment